The program described herein will train postdoctoral fellows for a career in academic oncology. Candidates with an M.D. or both an M.D. and Ph.D. degrees who have completed training in internal medicine will be admitted to the three-year program. ? ? The first year of the program consists of an intensive experience in clinical oncology. During the remainder of the program, the trainees will devote the majority of their time to research-based study, either in the laboratory or in a clinical setting. Fellow stipend support for the research training is provided by this grant. More than three years of training is often required to complete a research project and to become competitive for an academic position. Trainees and their preceptors obtain support beyond this training grant for these additional years. ? ? For each fellow, research training will be supervised by a full-time faculty member in the Division of Oncology, or by one of a number of associate faculty members at Stanford University representing the basic science disciplines relevant to cancer, such as biological sciences, biochemistry, developmental biology, genetics, immunology, pathology, hematopoietic stem cell transplantation, disease prevention, biostatistics, bioinformatics, genomics, or radiation oncology. At the conclusion of their training, individuals will be prepared for careers as independent investigators at the forefront of science and medical oncology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009287-27
Application #
6712066
Study Section
Subcommittee G - Education (NCI)
Program Officer
Gorelic, Lester S
Project Start
1978-09-30
Project End
2008-02-29
Budget Start
2004-03-01
Budget End
2005-02-28
Support Year
27
Fiscal Year
2004
Total Cost
$360,363
Indirect Cost
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Moraga, Ignacio; Wernig, Gerlinde; Wilmes, Stephan et al. (2015) Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Cell 160:1196-208
Pachynski, Russell K; Scholz, Alexander; Monnier, Justin et al. (2015) Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model. J Vis Exp :
Corces-Zimmerman, M Ryan; Hong, Wan-Jen; Weissman, Irving L et al. (2014) Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A 111:2548-53
Koontz, Michael Zach; Horning, Sandra J; Balise, Raymond et al. (2013) Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol 31:592-8
Pachynski, Russell K; Zabel, Brian A; Kohrt, Holbrook E et al. (2012) The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. J Exp Med 209:1427-35
Harshman, Lauren C; Bepler, Gerold; Zheng, Zhong et al. (2010) Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. BJU Int 106:1805-11
Vinayak, Shaveta; Ford, James M (2010) PARP Inhibitors for the Treatment and Prevention of Breast Cancer. Curr Breast Cancer Rep 2:190-197
Srinivas, Sandy; Harshman, Lauren C (2009) A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma. Chemotherapy 55:321-6
Harshman, Lauren C; Kuo, Calvin J; Wong, Bryan Y et al. (2009) Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma. Cancer Invest 27:851-6
Vinayak, Shaveta; Kurian, Allison W (2009) Statins May Reduce Breast Cancer Risk, Particularly Hormone Receptor-Negative Disease. Curr Breast Cancer Rep 1:148-156

Showing the most recent 10 out of 13 publications